Sakar Healthcare Limited has informed the Exchange about Investor Presentation on the Unaudited Financial Results for the period ended 30th September 2025.
To The Manager Listing Compliance Department National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai-400051, India
Symbol: SAKAR
Date: 11th November, 2025
Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Presentation on the Unaudited Financial Results.
Please find attached the presentation on the Unaudited Financial Results (Consolidated and Standalone) for the quarter and half year ended September 30, 2025.
This is submitted for your information and records.
Thanking You,
Yours faithfully, FOR, SAKAR HEALTHCARE LIMITED
BHARAT SONI COMPANY SECRETARY AND COMPLIANCE OFFICER
SAKAR HEALTHCARE LIMITED
Investor Presentation | Q2FY26
Safe Harbor
This presentation and the accompanying slides (the “Presentation”), which have been prepared by Sakar Healthcare Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.
This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.
Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict.
These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks.
The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.
2
Company Overview
From Vision to Value: Sakar Healthcare at a Glance
• Founded by Mr. Sanjay Shah, Sakar Healthcare has evolved from a contract manufacturer into an API-integrated pharmaceutical
organization with a strong presence across oral solids, injectables, and oncology formulations.
• Over two decades, the company has built a reputation for credibility, compliance, and precision, supported by world-class WHO
and EU-GMP certified facilities in Gujarat and a global network of partnerships across regulated markets.
• The establishment of a state-of-the-art oncology facility at Bavla, equipped with integrated API and FDF capabilities, marks a defining milestone in Sakar’s transformation. This expansion elevates the company from a reliable formulation partner to a vertically integrated player in the global oncology space — combining scientific innovation, scalable manufacturing, and sustainable operations.
• As it enters its next phase of growth, Sakar Healthcare stands positioned for onco-led value creation, leveraging its legacy of
quality and research excellence to deliver specialized, high-compliance healthcare solutions worldwide.
292+ Product Registrations MAs
200+ Dossiers filed (in process)
75+ International Partners Network
60+ Country Presence (Emerging Markets)
25+ Therapeutic Segments Coverage
55 Oncology Molecules Development to Launch
4
Leadership Team that Drives Growth
Sakar is at crux of next phase of growth, prepared to enter the niche segment of Oncology to cater to humanity. Sakar is well equipped to deliver High Precision Research works, suitably followed by Technology Transfer and Scale-up to commercialize Anti-Cancer products worldwide.“
Mr. Sanjay Shah Chairman & MD
Mr. Aarsh Shah JT. MD
Mrs. Rita Shah Director
Mr. Sunil Marathe Technical Director
Mr. Dharmesh Thaker CFO
Mr. Bikramjit Ghosh VP-Strategy & Business Development
5
Vision, Mission & Values
Vision
To become a global healthcare
organization based on three
pillars- people, partnership and
performance; making lives
healthy happy and more
meaningful by providing world
class healthcare solutions.
Mission
To strengthen our core
competencies to become the
preferred choice in existing
partnerships and explore new
market opportunities to expand
range of products and services-
respecting laws, protecting
environment and benefitting
mankind
Values
Committed team
Loyal to partners
Focused on results
Innovative approach
Diversified Model
Sakar Healthcare operates a diversified business model comprising CDMO Services, Own Brand Exports and Product Development Technology Transfer enabling a balance between stability and strategic growth.
CDMO / CMO Services
Sakar Healthcare provides Contract Development and Manufacturing (CDMO/CMO) services to leading multinational and domestic pharmaceutical companies. The company’s integrated setup enables product development, scale-up, and regulatory dossier support under global compliance standards. This vertical ensures consistent capacity utilization and steady recurring revenues.
Own Brand Exports – The Growth Driver
Sakar markets its own branded formulations across 60+ countries, building brand equity and higher-margin revenue streams. The company’s global footprint spans APAC, Latin America, Africa, CIS, and Europe, positioning it as a preferred partner in both branded and generic markets.
Licensing / Product Development
Sakar Healthcare co-develops product under patent non-infringing set and effect Technology Transfer or scale up to commercial batches based on partner requirements. Sakar License out developed CTD dossiers.
7
Sakar’s Go-To Market Strategy
MODELS
MARKETS
PRODUCTS
Licensing & Supply Agreement
Contract Development / Research & Manufacturing Service
Contract Development/ Manufacturing Service
MAH & Distribution
Profit Sharing
Co-development & Technology transfer
EU and the UK
MENA
AFRICA
LatAm and Canada
APAC
CIS
Oncology Oral solids
Oncology Oral liquids
Oncology liquid injections
Oncology Lyophilized Injection
Oncology bulk drug
Oncology API
8
A Differentiated Solutions Provider
Platform Integration
Pipeline Strength
EU-GMP certified oncology FDF facility with integrated API
Ready EU CTD dossiers with 11 global Marketing Authorizations granted
First patent received; APIs developed with 16 written regulatory confirmation
55 oncology molecules developed; 32 dossiers ready for launch
Developing Liposomal (Doxorubicin) & HME products (Apalutamide, Olaparib, Enzalutamide)
Focused on development of non-infringing patent formulations for regulated markets
Profitability & Partnerships
Purpose & Technology
Diversified model: LSA, CDMO, CRAMS, tech transfer, profit sharing
Oncology delivers ~2x higher margins vs. general formulations
Shift towards own brand exports (70%) enhancing profitability
Advanced Flow Chemistry (Vapourtech, UK) and GEA granulation lines
Toffolo lyophilizes, Di-Dietrich glass reactors ensure global compliance
Green Chemistry, ZLD & solar systems driving sustainable manufacturing
9
Trusted by Pharma Leaders
Zydus Lifesciences Limited
Torrent Pharmaceuticals Ltd.
Intas Pharmaceuticals Ltd.
German Remedies Ltd.
Cadila Pharmaceuticals Ltd.
Strides Arcolab Limited
Merck Limited
Pharos Pharmaceutical
Abbott India Ltd.
Indoco Remedies Limited
USV Ltd.
Bharat Serums and Vaccines Limited
Baxter
Biochem
Emcure Pharmaceuticals Limited
Cipla Limited
IPCA Laboratories Ltd.
WOCKHARDT Ltd.
Glenmark Pharmaceuticals Limited
Ferring Pharmaceuticals
10
Our Long Standing Client Association
19
19
20
16
15
14
13
13
12
9
8
11
Oncology – The Future with Sakar
Oncology – the driving growth engine
Oncology lies at the core of Sakar Healthcare’s transformation. As the global cancer burden continues to rise, the need for safer, more accessible, and effective therapies has never been greater.
Global Oncology Market (USD Bn)
With the growing prominence of biologics, cytotoxic, and complex generics, oncology presents one of the most compelling opportunities in pharmaceuticals—defined by high entry barriers, limited competition, and superior profitability.
For Sakar, entering the oncology space is not merely a business expansion—it represents a deliberate shift toward value-driven innovation and scientific purpose. Our EU-GMP approved Bavla facility, equipped with integrated API and FDF capabilities and advanced flow chemistry systems, enables seamless progression from research to commercialization under one roof.
Oncology in Indian Pharmaceutical landscape
Rising cancer incidence -In India, projected numbers for cancer patients is expected to rise from approximately 1.46 million in 2022 to 1.57 million in 2025.
E oncology drugs market is a major segment, with a projected value of $7.8 billion by 2030.
E NGS (Next-Generation Sequencing) market, particularly for targeted and gene panel sequencing, is also experiencing rapid growth, with a CAGR of 18% from 2024 to 2030.
Growing awareness about cancer, early detection, and the use of advanced diagnostic technologies are contributing to market growth.
371
208
2023
2030
Indian Oncology Market (USD Bn)
10.6
3.6
2022
2030
13
Sakar Oncology - Building the Future of Cancer Care
A research-driven, API-integrated, EU-GMP approved oncology FDF unit. Empowering global access to high-potency cancer therapies through precision research, advanced manufacturing, and sustainable innovation.
Strategic Overview
Portfolio Strength:
Annual Production
Facility:
•
•
•
•
Bavla, Gujarat – EU-GMP approved, vertically integrated oncology plant Product Capability: Oral solids, oral liquids, sterile injections (liquid & lyophilised), and oncology APIs (De- Dietrich glass reactors for complex oncology molecules) R&D Excellence: Integrated F&D, ADL, and R&D labs equipped with Flow Chemistry (Vapourtec, UK) Innovation Focus: Liposomal, HME- based, and cytotoxic oral liquid formulations to enhance patient compliance and bioavailability
55 oncology products developed in- house 32 ready for global launch 11 Marketing Authorisations (MAs) granted in EU and worldwide
APIs – 12.3 MT Oral solids – 97 million tablets, 29 million capsules Sterile injectables – 13 million vials Lyophilized – 22,000 vials per cycle (10 ml)
Key Differentiators
Vertically integrated from API to Finished Dosage
High containment (OEL Level 4) facility ensuring safety and compliance
Green Chemistry adoption for energy efficiency and waste reduction
Technology Transfer & Scale- Up ready labs supporting CRAMS, CDMO, & co-development models
In-house EU-CTD dossier preparation with bioequivalence studies from EMA/USFDA- approved CROs
14
Liquid / Lyophilised Injectable Unit - Oncology
Manufacturing Capacity (Cytotoxic injections)
Container Size
2ml to 10 ml
20ml / 30 ml
Lyophilized Product Capacity
Container Size
10 ml
Capacity Per Hour
7200
3000
Capacity / Cycles
22000 Vials
Eurovent certified AHU
Water system-two pass RO with EDI
ETP (zero-discharge)
Significance of the Unit
15
Oral Solid Unit - Oncology
Manufacturing Capacity (Cytotoxic OSD)
ORAL SOLID UNIT - Oncology
Bulk Drug
Tablet
Capsule Filling
Blister Packing
Bottle Packing
Capacity
6.5-120kg/Shift
324000 tablets/Shift
96000 capsules/Shift
324000 tablets/Shift
324000 tablets/Shift
EU-GMP Approved Oncology OSD Unit
The facility meets European regulatory standards, reflecting global manufacturing compliance. Its design allows seamless scale-up from pilot to commercial batches, reducing technology transfer challenges. This ensures faster market entry and reliability in regulated supply chains.
Containment and Isolation Systems for OEL Compliance
Operations are performed in fully contained suites to safely handle high-potent APIs. The setup maintains operator and environmental protection, achieving required OEL standards upto level 4. Such containment capability differentiates Sakar as a trusted oncology manufacturer.
Fully Automatic Line with Global Machinery Integration
The plant features automated operations from granulation to final packing. Equipment sourced from GEA, Glatt, IMA, ACG, and Sejong ensures consistency and quality precision. This high degree of automation minimizes human intervention and product variability.
Oral Liquid Oncology Section with Advanced Compounding
Includes a 500L compounding vessel equipped with an in-line homogenizer and filtration system. The system supports viscous and sensitive oncology liquids, maintaining uniformity and stability. This adds flexibility to Sakar’s oncology portfolio by covering both solid and liquid dosage forms.
16
Oncology Dossier List
Sr. OSD Product list
Strength
Sr.
Injection Product list
Strength
Lenalidomide Capsule
Imatinib Tablets 1 2 Gefitinib Tablet Erlotinib Tablet 3 4 Abiraterone Tablets 5 6 Anastrazole Tablet Letrozole Tablet 7 Tamoxifen Tablet 8 Sunitinib Capsule 9 10 Capecitabine Tablet** 11 Hydroxyurea Capsule 12 Methotrexate Tablet 13 Dasatinib Tablet** 14 Temozolamide Capsule** 15 Enzalutamide Tablet** 16 Mercaptopurine Tablet #
400mg ,100mg 250mg 150mg, 100mg 500mg, 250mg 25mg, 2.5mg, 5mg, 10mg, 15mg, 20mg 1mg 2.5mg 20mg, 10mg 50mg, 25mg, 12.5mg 500mg 500mg, 250mg 2.5mg, 5mg, 7.5mg, 10mg 20mg, 50mg, 70mg, 80mg, 100mg 100mg, 250mg 40mg 50mg
1 Docetaxel Injection 2 Gemcitabine Injection* 3 Gemcitabine for Injection 4 Irinotecan Injection 5 Carboplatin Injection 6 Oxaliplatin Injection 7 Doxorubicin for Injection* 8 Paclitaxel Injection 9 Pemetrexed for Injection* 10 Bortezomib for Injection* 11 Methotrexate Injection! 12 Cytarabine Injection! 13 Cisplatin Injection! 14 Mitomycin for Injection*! 15 Azacitidine Injection*! 16 Doxorubicin Solution for Injection!
80mg/4ml, 20mg/ml, 160mg/8ml 200mg/vial, 1gm/vial 1000mg/26.3ml 100mg/5ml, 40mg/2ml 450mg/45ml, 150mg/15ml, 50mg/5ml, 600mg/60ml 50mg/10ml, 100mg/20ml 50mg/vial 30mg/5 ml, 100mg/16.7ml, 300mg/50ml, 260mg/43.33ml 500mg/vial, 100mg/vial 3.5mg/vial 50mg/2ml 100mg/1ml, 500mg/5ml, 2gm/20ml, 1gm/10ml 100mg/100ml, 50mg/50ml, 25mg/25ml, 10mg/10ml 2mg/vial, 10mg/vial, 40mg/vial 100mg/vial 10mg/5ml, 50mg/25ml
BE Completed-Bold
# BE Study Completion by Nov-2025
**Ready to Conduct BE Study
* Lyophilised Injection
! Under Stability Study
Sr. Product Developed in-house, PV Planned 1 Doxorubicin HCl Liposome Injection Bendamustine for Injection Lyophilised 2 Sorafenib Tablet 3 Lapatinib Tablet 4 Palbociclib Tablet 5 Cyclophosphamide Tablet 6 Everolimus Tablet 7 Pazopanib Tablet 8 Exemestane Tablet 9 10 Bicalutamide Tablet
Strength 2mg/ml 25mg/vial, 100mg/vial 200mg 250mg 75mg, 100mg, 125mg 50mg 5mg, 10mg 200mg, 400mg 25mg 50mg
Capecitabine Oral Suspension
Sr. Oral Liquid Product List 1 2 Dasatinib Oral Suspension Enzalutamide Oral Solution 3 4 Erlotinib Oral Suspension 5 Hydroxycarbamide Oral Suspension Imatinib Oral Solution 6 7 Lenalidomide Oral Suspension 8 Mercaptopurine Oral Suspension 9 Methotrexate Oral Solution 10 Sunitinib Oral Suspension 11 Tamoxifen Citrate Oral Solution 12 Temozolomide Oral Suspension
Strength 200mg/ml 40mg/ml 32mg/ml 20mg/ml 100mg/ml 400mg/5ml 25mg/5ml 20mg/ml 2mg/ml 10mg/ml 20mg/10ml 30mg/ml
17
Growth Drivers
Industry Growth Drivers
Source: IBEF
Ageing Population & Chronic Disease Burden
01
Shift Toward Value-Based & Preventive Care
02
Over 1 in 6 people globally will be aged 60+ by 2030, driving demand for long- term care and chronic treatments.
Increasing adoption of data analytics and personalized medicine to improve outcomes and reduce costs.
R&D and Innovation Focus
03
Government & Policy Support
04
Global pharma R&D spending projected to exceed USD 280 billion by 2030, boosting innovation in specialty therapies.
Initiatives improving access, insurance coverage, and manufacturing incentives in emerging markets like India.
Growing CDMO/CRAMS Partnerships
05
Sustainability & Green Manufacturing
Outsourcing by global pharma expected to grow at 10–12% CAGR, enhancing manufacturing scalability.
Industry shift toward eco-friendly and zero-discharge production systems for global compliance.
06
19
Product Development Snapshot
Oral Solids
Injection
APIs
Liquid orals
22 products developed
21 products developed
22 APIs developed
12 products developed
16 EU CTD dossiers
16 EU CTD dossiers
15 with Written Confirmation
9 products in pipeline
9 products in pipeline
4 applied for CEP (3 in process)
• 11 Bio-study completed from EMA / US FDA approved CROs • RLD’s are from EU
20
Industry Overview
Indian Health Care (In US$ Billion)
Indian Pharmaceutical Market (US$ billion)
638
130
372
50
55
110
2016
2023
2025
2023
2025 P
2030 P
The sector is growing at a robust 17.5-22.5% CAGR, driven by innovation across hospitals, pharmaceuticals, and diagnostics
Rising income levels, an ageing population, growing health awareness and a changing attitude towards preventive healthcare is expected to boost healthcare services demand in the future
Indian pharmaceutical industry is known for its generic medicines and low- cost vaccines globally. Transformed over the years as a vibrant sector, presently Indian pharma ranks third in pharmaceutical production by volume
Drug Formulations and Biologicals stood at US$ 22.92 billion, accounting for 75% of total pharmaceutical exports in FY25
Source: IBEF
21
Green Chemistry – Engineering Sustainability
Green Chemistry 12 Principles
1
Prevent waste
2
Maximize atom economy
3
Less hazardous chemical syntheses
4
Safer chemicals & products
5
Safer solvents & reaction-conditions
6
Increase energy efficiency
Minimize potential 1 for accidents
12
Analyse in real time to prevent pollution
11
Design chemicals & products to degrade after use
10
Use catalysts
9
Avoid chemical derivatives (protein groups)
8
Use renewable feedstocks
7
Vapourtec R Series System, UK
Glass Line Reactors from De-Dietrich, Italy
OSD Containment Granulation and Compression Line, GEA, Belgium
Glatt-Autocoater, Germany
Tablet Capsule Inspection Machine by Sensum, Slovenia
Sterile Manufacturing Line with Lyophiliser, Tofflon
Kevin Roll Compacter
Bulk packaging Line IMA, Germany
Enables Green Chemistry
Adopted techniques like Flow-Chemistry (Vapourtech) - safer with small reaction volumes, low solvent-reagent, low risk of environment exposure
Containment manufacturing- lines or Isolators in place to support Green Chemistry principles
Designs and processes are in place to suit Green Chemistry objectives
Newly installed facility along with world class equipment, provides Sakar competitive edge
22
Key Investment Proposition
Fully Integrated API- FDF Manufacturing Ecosystem
Diverse product portfolio across 24+ Therapies
Sustainable and Green Chemistry Driven Operations
Oncology at the Core of Value Creation
Strong regulatory compliance (WHO GMP, EU GMP)
Strong International Footprint in 60+ countries
Trusted Global Partnerships and Long- Term Client Relations
23
Manufacturing Prowess
Liquid / Lyophilised Injectable Unit (Vials and Ampoules)
Manufacturing Capacity (SVP)
Ampoules
Vials
1ml & 2ml
3ml
5ml
2ml
5ml & 10ml
20ml & 30ml
18000
16000
14000
18000
15000
12000
Manufacturing Capacity Lyophilised
Vials
10ml
22000
30+
No. of Products in the Category
Significance of the Unit
Sublimation based lyophilization improves product shelf life and reconstitution quality.
Handles both liquid and lyophilized injectables under one roof
Equipped with Tofflon lyophilizer and ORABS technology – freeze drying with autoloading and unloading
HEPA filtered Class 100 environment ensures aseptic processing
25
Cephalosporin - Oral Solid Unit (Tablets, Capsules, Dry Syrups & Sachets)
Manufacturing Capacity
Process
Granulation
Blending
Compression
Filling
ALU- ALU packing
ALU- ALU packing
Dry Syrup
Capacity (kgs/shift)
500 Kgs/shift
1000 kgs /shift
1200000/shift
1200000/ shift
1200000/ shift
600000/shift
25000/shift
40
No. of Products in the Category
Core hub for oral solids with wide dosage flexibility (80–1500 mg tablets, 250–500 mg capsules).
Fully automated line from granulation to packing, minimizing contamination and material loss.
Offers packaging versatility – ALU- ALU, ALU-PVC, strip & dry syrup – suited for diverse market needs.
HEPA-filtered environment with controlled storage ensure
Significance of the Unit
26
Cephalosporin – Injectable Unit (Dry Powder)
Manufacturing Capacity
Container size
Capacity (per Hour)
250 mg
500 mg
1 gm / 2 gm
3 gm / 5 gm
14400
14400
11500
8500
Key sterile block for antibiotic dry powder vials (250 mg to 5 g range).
Ensures aseptic integrity with HEPA- controlled environment and segregated flows.
High-speed visual inspection (15,000 vials/hour) and automated packaging ensure quality and efficiency.
Controlled storage with humidity regulation maintains product stability and compliance
Significance of the Unit
27
18
No. of Products in the Category
Oral Liquid Unit (Syrup & Suspension)
Manufacturing Capacity
Volumes
10 ml
30 ml
60 ml
100 ml
200 ml
No of bottles/ Shift
75000
75000
50000
60000
30000
Key sterile block for antibiotic dry powder vials (250 mg to 5 g range).
Ensures aseptic integrity with HEPA- controlled environment and segregated flows.
High-speed visual inspection (15,000 vials/hour) and automated packaging ensure quality and efficiency.
Controlled storage with humidity regulation maintains product stability and compliance
Significance of the Unit
28
Financial Performance
Q2 & H1FY26 – Profit & Loss Statement
Revenue
+34.56%
4,278
5,756
1,150
1,135
EBITDA
-1.28%
INR in Lac
PAT
-5.35%
480
454
Q2FY25
Q2FY26
Q2FY25
Q2FY26
Q2FY25
Q2FY26
+31.42%
11,030
8,393
+8.38%
2,406
2,220
+27.78%
921
721
H1FY25
H1FY26
H1FY25
H1FY26
H1FY25
H1FY26
30
Q2FY26 – Consolidated Profit & Loss Statement
Particulars (Rs. lakhs)
Revenue from Operations
COGS
Gross Profit
Gross Profit Margin (%)
Employee Expenses
Other Expenses
EBITDA
EBITDA Margin (%)
Other Income
Depreciation
Finance Cost
Share of profit or (loss) from associates
Profit before Tax
Profit before Tax(%)
Tax
Profit After Tax
PAT Margin (%)
EPS (As per Profit after Tax)
Q2 FY26
Q2 FY25
5756.04
4277.81
Y-o-Y
34.6%
3040.64
2289.77
2715.4
1988.04
47%
834.19
745.82
46%
545.52
292.4
Q1 FY26
5273.62
2895.24
2378.38
45%
754.96
352.84
Q-o-Q
9.1%
H1 FY26
11029.66
H1 FY25
8392.58
Y-o-Y
31.4%
5935.88
4495.91
5093.78
3896.67
46%
46%
1589.15
1083.97
1098.66
592.69
1135.39
1150.12
-1.3%
1270.58
-10.6%
2405.97
2220.01
8.4%
20%
121.46
568.38
152.68
-
27%
37.29
511.9
164.4
-
24%
39.39
557.23
214.26
-
22%
160.85
26%
83.27
1125.61
1017.65
366.94
304.21
-
-
535.79
511.11
4.8%
538.48
-0.5%
1074.27
981.42
9.5%
9%
81.81
12%
31.48
10%
71.35
453.98
479.63
-5.3%
467.13
-2.8%
8%
2.03
11%
2.17
9%
2.11
10%
153.16
921.11
8%
4.14
12%
260.59
720.83
9%
3.27
27.8%
31
Q2FY26 – Consolidated Balance Sheet
Particulars (in Rs. lakhs) ASSETS Non-Current Assets Property, Plant and Equipment Goodwill Capital work-in-progress Investment Property Intangible Assets Intangible asset under development Non Current Financial Assets Deferred Tax Asset (Net) Non-Current Tax Assets (net) Other Non-Current Assets Total Non - Current Assets Current Assets Inventories Financial Assets Investments Trade Receivables Cash and Cash Equivalents Other bank balance Loans Other Financial Assets Contract Assets Other Current Assets Current tax asset (net) Total Current Assets Total Assets
Sep-25
Mar-25
Particulars (in Rs. lakhs)
Sep-25
Mar-25
31,711.7
30,434.93
1,703.36
1,670.35
765.64
461.07
30.06
30.06
1,186.11 35,396.87
56.97 32,653.38
4,452.65
4,359.24
3,198.52 0.83 20.77
3,072.3 10.16 20.77
1,790.14
9,462.91 44,859.78
- 1,410.25
8,872.72 41,526.10
Equity
Equity Share Capital
Other Equity
Money Received Against Share Warrant
Total Equity
Liabilities
Non-Current Liabilties
Financial Liabilities
(i) Borrowings
(ii) Lease Liabilities
(iii) Other Financial Liabilities
Deferred Tax Liabilities (net)
Provisions
Total Non-Current Liabilities Current Liabilities Financial liabilities (i) Borrowings (ii) Trade Payables (iii) Lease Liabilities (v) Other Financial Liabilities Other Current Liabilities Provisions Current Tax Liabilities (Net) Total Current Liabilities Total Equity and Liabilities
2,224.99
28,100.3
2,194.99
26,064.6
288
30,325.29
28,547.59
4,525.6
5,359.42
996.41
274.19
5,796.2
2,660.55 3,602.77
1,322 937.92
215.05 8,738.29 44,859.78
1,034.44
266.04
6,659.9
2,136.05 2,106.66
1,142 801.3
132.6 6,318.61 41,526.10
32
Q2FY26 – Consolidated Cash Flow Statement
Particulars (Rs. In lacs)
Cash Flow from Operating Activities
Profit before Tax
Operating Profit before Working Capital Changes
Changes in Working Capital
Cash Generated from Operations
Less: Direct Taxes paid
Net Cash from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activities
Net increase/ (decrease) in Cash & Cash equivalent
Add: Cash and cash equivalents as at beginning of the period
Add: Net effect of exchange gain on cash and cash equivalents
Sep-25
Sep-24
1,074.27
2,262.97
3,337.24
-278.53
3,058.71
-2,739.95
-328.08
-9.32
10.16
981.42
1,191.41
2,172.83
-63.08
2,109.75
-1,305.15
-798.42
6.18
25.79
Cash and cash equivalents
0.84
31.97
33
Historical Financial Highlights
Revenue from operations (INR in lacs)
Operating Profit (INR in lacs)
Consolidated PAT (INR in lacs)
17,758
15,335
12,823
13,336
9,474
2,900
3,300
3,800
2,300
5,000
1,750
1,501
1,074
1,276
1,167
FY21
FY22
FY23
FY24
FY25
FY21
FY22
FY23
FY24
FY25
FY21
FY 22
FY23
FY24
FY25
Debt to Equity (x)
Net-worth (INR in lacs)*
0.7
0.7
0.4
0.3
0.3
17,300
12,700
9,900
28,600
26,300
FY21
FY22
FY23
FY24
FY25
FY21
FY22
FY23
FY24
FY25
34
THANK YOU
Investor Presentation | Q2FY26
For further information, please contact:
Company :
Sakar Healthcare Limited CIN: L24231GJ2004PLC043861 Email – info@sakarhealthcare.com cs@sakarhealthcare.com
Investor Relations Advisors :
MUFG Intime India Private Limited A part of MUFG Corporate Markets, a division of MUFG Pension & Market Service Mr. Nikunj Seth nikunj.seth@in.mpms.mufg.com
sejal.bhattar sejal.bhattar
Mr. Sejal Bhattar sejal.bhattar@in.mpms.mufg.com
Meeting Request
Link
LinkLink Link